Wird geladen...
A single arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma (RCC)
BACKGROUND: Everolimus ,an oral inhibitor of mammalian target of rapamycin (mTOR), and sunitinib, an oral inhibitor of VEGF/PDGF receptor tyrosine kinase signaling, have both been shown to provide clinical benefit in patients with advanced RCC. We sought to determine the safety and efficacy of combi...
Gespeichert in:
| Veröffentlicht in: | Clin Genitourin Cancer |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4754968/ https://ncbi.nlm.nih.gov/pubmed/26174223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.12.011 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|